After months of melodrama and acrimonious exchanges between Jim Cornelius and Carl Icahn, Eli Lilly, not Bristol-Myers Squibb, will acquire ImClone and gain access to the multibillion dollar Erbitux
read more » Discuss Add this link to...Bury Add to:
| Bookmarks